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CLINICAL SCIENCE
Endophenotypes and serotonergic polymorphisms
associated with treatment response in obsessive-
compulsive disorder
Fa´bio M. Corregiari, Ma´rcio Bernik, Quirino Cordeiro, Homero Vallada
Hospital das Clı´nicas da Faculdade de Medicina da Universidade de Sa˜o Paulo, Instituto de Psiquiatria, Sa˜o Paulo/SP, Brazil.
OBJECTIVES: Approximately 40-60% of obsessive-compulsive disorder patients are nonresponsive to serotonin
reuptake inhibitors. Genetic markers associated with treatment response remain largely unknown. We aimed (1) to
investigate a possible association of serotonergic polymorphisms in obsessive-compulsive disorder patients and
therapeutic response to selective serotonin reuptake inhibitors and (2) to examine the relationship between these
polymorphisms and endocrine response to intravenous citalopram challenge in responders and non-responders to
serotonin reuptake inhibitors and in healthy volunteers.
METHODS: Patients with obsessive-compulsive disorder were classified as either responders or non-responders after
long-term treatment with serotonin reuptake inhibitors, and both groups were compared with a control group of
healthy volunteers. The investigated genetic markers were the G861C polymorphism of the serotonin receptor 1Db
gene and the T102C and C516T polymorphisms of the serotonin receptor subtype 2A gene.
RESULTS: The T allele of the serotonin receptor subtype 2A T102C polymorphism was more frequent among
obsessive-compulsive disorder patients (responders and non-responders) than in the controls (p,0.01). The CC
genotype of the serotonin receptor subtype 2A C516T polymorphism was more frequent among the non-responders
than in the responders (p,0.01). The CC genotype of the serotonin receptor subtype 1Db G681C polymorphism was
associated with higher cortisol and prolactin responses to citalopram (p,0.01 and p,0.001, respectively) and with a
higher platelet-rich plasma serotonin concentration among the controls (p,0.05). However, this pattern was not
observed in the non-responders with the same CC genotype after chronic treatment with serotonin reuptake
inhibitors. This CC homozygosity was not observed in the responders.
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INTRODUCTION
Despite the efficacy of serotonin reuptake inhibitors (SRIs)
in treating obsessive-compulsive disorder (OCD) (1), 40-60%
of these patients are unresponsive to treatment (2).
Individual genetic differences may play a role in determin-
ing both clinical responses to medications and adverse side
effects. However, few genetic factors have been identified,
and the mechanisms underlying clinical failure remain
largely unknown (3).
One way to assess the brain serotonergic system is
through the identification of endophenotypes with a variety
of tests, such as the neuroendocrine challenge test. In a
previous study (4), our group reported that cortisol
response to citalopram in OCD patients who are responsive
to SRIs was comparable to the response of the control
subjects who had no mental disorders. In contrast, OCD
patients who were therapeutically unresponsive after
several long-term SRI trials demonstrated a blunted cortisol
response to citalopram.
The goal of the present study was (1) to investigate
whether there is an association of serotonergic polymorph-
isms and treatment response to SRIs in OCD patients and (2)
to examine the association between the selected polymorph-
isms and endocrine responses to an acute intravenous (IV)
citalopram challenge.
SUBJECTS AND METHODS
Samples
Outpatients who met the DSM-IV5 diagnostic criteria for
OCD and were between 18 and 65 years of age were classified
according to their therapeutic response to long-term SRI
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treatment (clomipramine, fluoxetine, fluvoxamine, citalo-
pram, sertraline or paroxetine) as either non-responders
(NRs) or responders (RPs) according to the following
criteria:
– NR: no more than a 25% reduction in the Y-BOCS (6)
score after at least: two different selective serotonin
reuptake inhibitors (SSRIs) at a maximum or maximum
tolerated dose for at least 8 weeks and (2) clomipramine
at a maximum or maximum tolerated dose for at least 8
weeks (the NRs in this study have received an average of
13.27¡9.5 years of treatment).
– RP: a Y-BOCS score of less than 9 and a Sheehan
Disability Scale (7) score of less than 10 after treatment
with an SRI and stable for at least 2 months.
We evaluated 239 OCD patients from our own service or
referred to us for specialized treatment. From these, 60
patients met inclusion criteria. OCD patients who did not
meet the criteria for either NR or RP were excluded from
this study. Patients with severe depression (HAMD-21.25),
affective bipolar disorder, schizophrenia, schizoaffective
disorder, active substance abuse or dependence were
excluded. Patients currently taking fluoxetine were
excluded because of the drug’s long half-life.
We selected 30 age- and gender-matched subjects who
were free of mental and medical disorders as a control
group (CN). The control subjects had never used psycho-
tropic medications and were free from any medication for at
least one month.
The clinical characteristics of patients and controls are
presented elsewhere (4). All medications including SRIs
(except for low-dose bedtime benzodiazepines, which were
maintained at a consistent dose throughout the study) were
gradually tapered off, and the patients were observed over a
one-week washout period before the challenge test. Females
were tested in the early follicular stage of their menstrual
cycle (defined as the period between the third and tenth day
of the cycle).
Challenge test procedure
Challenge test procedures began at 8:00 AM, after an
overnight fast. After a peripheral intravenous insertion and
60 minutes of rest, blood sampling began at 9:00 AM. The
samples were collected at 20-minutes intervals during 180
minutes. The citalopram infusion began 20 minutes after the
first blood sample had been collected. Twenty milligrams of
citalopram were diluted in 250 ml of saline and infused over
60 minutes. Subjects were tested in a reclining position and
were kept awake.
Plasma cortisol, prolactin and growth hormone (GH)
levels were quantified by standard immunoradiometric
assays at -20, 0 (onset of the citalopram infusion), 20, 40,
60, 80, 100, 120, 140, and 160 minutes. The serotonin
concentration in platelet-rich plasma was measured through
high-performance liquid chromatography with a Shimadzu
10Vp system in conjunction with a fluorescence detector
(Shimadzu RF-10A XL). The platelets were counted on a cell
counter Ac T diff Coulter (Beckman Coulter) to normalize
the results.
Investigated polymorphisms
The investigated polymorphisms included the G861C
polymorphism (rs6296) of the serotonin receptor subtype
1Db (HTR1B) gene and T102C (rs6313) and C516T (rs6305)
polymorphisms of the serotonin receptor subtype 2A
(HTR2A) gene.
Genotyping
Genomic DNA was extracted using a salting out method
(8). There were technical problems when genotyping three
responders and three control subjects. Therefore, some of
the gene variants were not analyzed for these samples.
However, two resistant patients (excluded in the challenge
test because of pairing issues) were included in the gene
frequency analysis.
HTR1B (G861C). The G861C polymorphism of the gene
coding for the serotonin receptor subtype 1Db was
genotyped according to the procedures described by
Mundo et al. (9). The 548-bp PCR fragment was digested
with Hinc II restriction enzyme. The alleles were detected
after separation on an agarose gel, and the G allele was the
undigested fragment.
HTR2A (T102C). Genotyping of the T102C polymorphism
of the gene coding for the serotonin receptor subtype 2A
was performed using the primers and conditions described
by Warren al. (10). After amplification, the PCR products
were digested with Msp I. The fragment sizes were a single
342-bp band for the 102T allele and two bands (216 bp and
126 bp) for the 102C allele.
HTR2A (C516T). The primers and PCR conditions used
for the analysis of the C516T polymorphism of the gene
coding for the serotonin receptor subtype 2A were
described by Arranz et al. (11). The amplified DNA
products from the patient and control samples were
digested with Sau 96I restriction enzyme (New England
Biolabs Inc., cat. R0165S). The C516 allele (digested PCR
product) showed 109-bp and 87-bp fragments, whereas the
T516 allele remained uncut.
To confirm the genotyping results for all the investigated
markers, we used a commercial 50–bp DNA ladder (GE
Healthcare Life Sciences, product code: 27-4005-01). After
the restriction enzyme cleavage reaction, the fragments of
each marker were separated electrophoretically on an
agarose gel and visualized under a UV light. All of the
genotyping results were interpreted by two independently
trained research technicians. The same person genotyped all
samples. The genotyping process was repeated when a
disagreement arose (e.g., the T516C genotyping of two
heterozygous individuals was repeated during the analysis).
Statistical analysis
The prolactin and cortisol responses to citalopram were
measured as maximal percentage variation (max%D).
Because of the null values observed at baseline, GH
responses were measured as the maximal variation over
baseline (maxD). The continuous variables were analyzed
using an analysis of variance (ANOVA) or a paired t-test
when appropriate. Friedman, Mann-Whitney or Wilcoxon
matched tests were used when a non-parametric analysis
was required. A general linear procedure was used to
perform a two-way ANOVA and post-hoc analysis.
Categorical data were analyzed using a chi-square test
and a chi-square partition. The significance level was 5%
and based on two-tailed tests. A standard deviation was
calculated to indicate variability. A test for deviations from
the Hardy-Weinberg equilibrium was performed using the
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HWE program (12). The analysis was performed using
EpiInfo version 6.0 and SPSS version 15.0.
ETHICS
The protocol was in accordance with Declaration of
Helsinki for research with human subjects and approved
by the Ethics Committee at the Hospital das Clı´nicas,
University of Sa˜o Paulo Medical School (CAPPesq). All
subjects gave written, informed and free consent.
RESULTS
Hardy-Weinberg Equilibrium
The genotypic distributions of the HTR2A C516T, HTR2A
T102C, and HTR1B G681C polymorphisms were in Hardy-
Weinberg equilibrium (HWE) in the CN (p.0.05). The case
group was in HWE for all polymorphisms except for the
HTR2A T102C polymorphism (p= 0.0001).
Frequency of Polymorphisms Distributions
The patient and control polymorphism frequency data are
presented in Table 1. In the patients, the 102CC genotype is
less frequent than in the CN (p,0.001 after a chi-square
partition), and the heterozygosity frequency was higher
(p= 0.02), with no difference in the 102TT genotype. The
frequency of the T allele was higher in the patients than in
the CN (p,0.01). In Table 2, the allele frequency of each
DNA marker in the OCD patients group was subdivided
into responders versus non-responders for the SRIs. The
516CC genotype was more frequent, and consequently,
the heterozygosity frequency was reduced because there
were no patients with a 516TT genotype among the non-
responders versus the responders (p,0.01). After a chi-
square partition, CC homozygosity for the HTR1B G681C
polymorphism was more frequent among non-responders
versus responders (p= 0.018).
Relationship among genetic polymorphisms, study
groups and endocrine/serotonin variables
Relationship with basal hormonal/serotonin levels
The basal levels of serotonin, prolactin, growth hormone
(GH), and cortisol and the interactions with the investigated
polymorphisms were compared among the three study
groups (NR, RP, and CN). No associations were found
among the groups; polymorphisms; and prolactin, GH or
cortisol basal levels. The CN showed the highest platelet-
rich plasma serotonin concentration (p,0.001). The only
significant interaction was observed between the groups
and the HTR1B G681C polymorphism (p= 0.022; Table 3),
with the highest serotonin level observed among the CC
homozygous of the CN (558.01 ng/ml) and the lowest level
observed among non-responders with the same genotype
(74.68 ng/ml).
Relationship with endocrine response to
intravenous citalopram
Prolactin, GH and cortisol responses to citalopram and
interactions with the investigated polymorphisms were
compared among the three groups (NR, RP, and CN).
As reported previously (4), the prolactin increase (as a
percentage of the baseline) was greater in the CN than in the
responder and the non-responder groups (p= 0.017 for NR
versus CN; p= 0.004 for RP versus CN). However, there was
no difference between the responder and the non-responder
groups.
The prolactin response was not associated with any allele or
genotype among the C516T HTR2A and T102C HTR2A
polymorphisms. However, the subjects with CC homozygos-
ity for the G681C HTR1B polymorphism showed a more
intense prolactin response to citalopram (p,0.01 for both CC
Table 1 - Polymorphism frequency among patients and
controls.
Genotypes Patients (RP + NR) (%) CN (%) p-value
HTR2A C516T
CC 48 (81.4) 26 (92.9) 0.16
CT 11 (18.6) 2 (7.1)
TT 0 (0) 0 (0)
HTR2A T102C
TT 17 (28.3) 6 (20.0) ,0.001
TC 43* (71.7) 14* (46.7)
CC 0** (0) 10** (33.3)
HTR1B G681C
CC 6 (10.2) 2 (6.9) 0.88
CG 24 (40.7) 12 (41.4)
GG 29 (49.2) 15 (51.7)
Alleles
HTR2A C516T 0.18
C 107 (90.7) 54 (96.4)
T 11 (9.3) 2 (3.6)
HTR2A T102C 0.007
T 77 (64.2) 26 (43.3)
C 43 (35.8) 34 (56.7)
HTR1B G681C 0.69
C 36 (30.5) 16 (27.6)
G 82 (69.5) 42 (72.4)
Note: RP=Responders; NR=Non-responders; CN=Controls. *p=0.02 after
a chi-square partition for heterozygosity; **p,0.001 after a chi-square
partition for the CC genotype.
Table 2 - Polymorphism frequency among non-
responders and responders.
Genotypes NR (%) RP (%) p-value
HTR2A C516T ,0.01
CC 30 (93.8) 18 (66.7)
CT* 2 (6.2) 9 (33.3)
HTR2A T102C 0.54
TT 8 (25.0) 9 (32.1)
TC* 24 (75.0) 19 (67.9)
HTR1B G 681 C 0.054
CC 6** (18.8) 0** (0)
CG 11 (34.4) 13 (48.1)
GG 15 (46.9) 14 (51.9)
HTR1B G 681 C 0.018
CC 6 (18.8) 0 (0)
GC or GG 26 (81.2) 27 (100)
Alleles
HTR2A C516T 0.01
C 62 (96.9) 45 (83.3)
T 2 (3.1) 9 (16.7)
HTR2A T102C 0.68
T 40 (62.5) 37 (66.1)
C 24 (37.5) 19 (33.9)
HTR1B G681C 0.16
C 23 (35.9) 13 (24.1)
G 41 (64.1) 41 (75.9)
Note: RP =Responders; NR=Non-responders; CN=Control. *No TT
genotype for HTR2A C516T and no CC genotype for HTR2A T102C were
observed among patients; **p,0.05 for the CC genotype after a chi-
square partition.
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versus CG and CC versus GG genotype, Table 4). A significant
group-genotype interaction was observed (p,0.001; Table 4)
when the nine subgroups, corresponding to the combination
group-genotype, were compared. The CC genotype was not
detected among the responders. The control-CC genotype
subgroup showed the highest prolactin response, even
compared with the other two control subgroups (control-CG
genotype and control-GG genotype; p,0.001 after a Bonferroni
correction; Table 4).
The GH response to citalopram failed to show differences
among the groups and was not associated with any of the
studied polymorphisms.
As reported previously, the peak secretion of cortisol as
measured through maximal percentage variation was less
pronounced in the non-responders compared with the
responders (p= 0.015) and was smaller compared to the
CN (p= 0.052). There was no significant difference for the
CN vs. the responder group (p= 0.53) (4). The cortisol
maximal percentage variation was unrelated to the HTR2A
C516T and T102C polymorphisms. A more intense cortisol
response was observed in those subjects who were homo-
zygous for the HTR1B G681C polymorphism (p= 0.011 for
overall comparison). A significant group-genotype interac-
tion was observed (p= 0.001). The control-CC subgroup
showed the most intense cortisol response, higher than the
other control group genotypes (p#0.003 for all comparisons
after a Bonferroni correction; Table 5).
DISCUSSION
The present study investigates an association between
DNA markers, the endocrine response to citalopram,
peripheral serotonin concentration and the responsivity
status in OCD patients and controls. As far as we know, this
is the first study to examine these associations in OCD
patients.
Few studies have investigated serotonergic polymorph-
isms and SRI treatment responses in OCD patients. Denys
et al. (13) reported that in paroxetine-treated patients, the
majority of the responders were homozygote for the G allele
of the 1438 G/A polymorphism of the HTR2A gene.
Cavallini et al. (14) found no association between the
Cys23Ser polymorphism of the HTR2C gene and a
therapeutic response to clomipramine.
An important finding in our study, which was previously
unreported, was the absence of CC homozygosity of the
Table 3 - Platelet-rich plasma serotonin levels in the three
study groups, stratified by the G681C HTR1B
polymorphism.
G681C HTR1B
Polymorphism
Genotype Mean (ng/ml) ¡Standard Deviation (%) N
NR C C 74.68¡49.13 5
C G 121.73¡79.37 11
G G 184.39¡162.59 14
Total 143.13¡127.12 30
RP C G 163.26¡128.90 13
G G 175.36¡124.81 12
Total 169.07¡124.44 25
CN C C 558.01¡80.12 2
C G 540.52¡220.26 12
G G 390.63¡117.03 15
Total 464.20*¡179.33 29
Total C C 212.78¡241.45 7
C G 276.32¡242.76 36
G G 257.20¡167.96 41
Total 261.69¡207.28 84
Note: RP=Responders; NR=Non-responders; CN=Control. The platelet-
rich plasma level of serotonin was statistically higher in the CN (*p,0.001;
F = 14.63) than in the other two groups. A significant interaction between
the groups and the G681C HTR1B polymorphism was observed (p=0.022;
F = 3.383), with the highest serotonin level observed among the CC
homozygous of the CN and the lowest among the NR group with the
same genotype.
Table 4 - A comparison of the prolactin maximal percent
of variation among the eight subgroups based on the
three groups of participants and the G681C HTR1B
polymorphism genotypes.
Group
HTR1B G681C
Polymorphism Genotype Mean¡Standard Deviation (%) N
NR C C 20.53¡26.63 5
C G 14.91¡28.43 11
G G 18.25¡36.09 14
Total 17.41¡31.06 30
RP C G 23.96¡45.06 13
G G 9.75¡15.79 12
Total 17.14¡34.38 25
CN C C 317.48***¡206.23 2
C G 60.77¡101.17 12
G G 33.21¡38.09 15
Total 64.22*¡106.62 29
Total C C 105.38**¡168.98 7
C G 33.47¡67.39 36
G G 21.23¡33.11 41
Total 33.49¡70.84 84
Note: RP=Responders; NR=Non-responders; CN=Control. The CN
showed a higher prolactin response overall (*p,0.01 for CN versus both
RT and RP after a Bonferroni correction). Subjects with a CC homozygosity
showed a higher prolactin response overall (**p,0.01 for both CC versus
CG and CC versus GG comparisons yield significant results after Bonferroni
correction). The interaction between group and genotype was significant
(p,0.001). In the post-hoc analysis, the control-CC subgroup was the only
significantly different group and showed a higher prolactin response than
all other subgroups (***p,0.001 after a Bonferroni correction).
Table 5 - A comparison of the cortisol maximal percent of
variation among the eight subgroups based on the three
groups of subjects and the HTR1B G681C polymorphism
genotypes.
Group
HTR1B G681C
Polymorphism
Genotype
Mean¡Standard
Deviation (%) N
NR C C -4.93¡8.76 5
C G 20.06¡51.04 11
G G 30.95¡71.75 14
Total 20.98¡58.14 30
RP C G 38.94¡66.79 13
G G 50.61¡65.96 12
Total 44.54¡65.26 25
CN C C 261.59*¡112.22 2
C G 51.92¡86.62 12
G G 48.83¡57.95 15
Total 64.78¡89.72 29
Total C C 71.21¡138.07 7
C G 37.50¡69.28 36
G G 43.24¡64.23 41
Total 43.11¡73.96 84
Note: RP=Responders; NR=Non-responders; CN=Control. *p#0.003 after
a Bonferroni correction compared with all other groups.
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HTR2A gene T102C polymorphism in both patient groups
(responders and non-responders), whereas it was present in
one-third of the CN (p,0.001). The T allele was more frequent
among patients than among controls (p,0.01). These findings
suggest that the presence of at least one T allele could be an
OCD risk factor. The 102TT genotype was more frequent
among patients than among controls (28.3% vs. 20.3%,
respectively), but this difference was not statistically sig-
nificant after a chi-square partition (p= 0.39). The study may
be underpowered to confirm an excess of 102TT homozygous
among the patients. The fact that the HTR2A T102C
polymorphism was not in HWE in the patients group may
be a concern. If deviations from HWE are present in the
control population, then one or more of the model assump-
tions may have been violated or that a genotyping error has
occurred. During our experiment, the genotyping process
was repeated when a disagreement arose between the
independently trained research technicians who interpreted
the data. However, a known homozygous sample was not
used as a control, which would have guaranteed the
genotyping accuracy. Notably, the CN is in HWE (p= 0.78).
Therefore, a genotyping error appears unlikely. In the present
study, the patient samples may not need to be in HWE
because the patients were not randomly selected from the
population (15). In other words, a deviation from HWE in the
case subjects may indicate an association of a locus with OCD
(16,17). Another reason for the lack of HWE could be ethnic
differences between the subjects and consequent sample
stratification. As noted, this reason could be the case in the
current study because we did not control for ethnic back-
ground. Interestingly, the HTR2A T102C polymorphism
lacked HWE, and this polymorphism was associated with
the disorder, suggesting that the association may be real.
Another novel finding was that an excess of CC
homozygosity and the C allele of C516T polymorphism of
the HTR2A gene was observed among the non-responders.
This finding may indicate that having at least one T allele
could be a factor that indicates SRI responsiveness during
OCD treatment.
Notably, our previous study found no differences in the
allele and genotype frequencies between OCD patients and
the control groups for the T102C HTR2A gene polymorphism
(18). Those results suggested that the C516T variant of the
HTR2A gene may be a genetic risk factor for OCD. Another
study by our group found no association between the
5HTTLPR and STin2 polymorphisms in the promoter region
of the serotonin transporter gene (SLC6A4), the G861C
polymorphism (rs6296) of HTR1B, the T102C (rs6113) and
C516T (rs6305) polymorphisms of HTR2A and the clomipra-
mine response in OCD patients (19). In the present study,
these divergences may be caused by differences in sample
characteristics with the refractory patients in the RT group
and the highly responsive patients in the RP group.
Finally, CC homozygosity for the HTR1B gene G681C
polymorphism showed another relevant finding regarding
the relationship between the endocrine response to citalo-
pram and the investigated groups, despite a low tendency
toward gene frequency discrepancies between responders
and non-responders (p= 0.054). This genotype was present
in only 6 of the 32 non-responders and was absent from the
responders. The effect of this genotype on the hormonal
response to IV citalopram, an indirect measure of serotonin
functioning, is notable. The subgroup of the controls with
the CC genotype (n = 2) showed the highest prolactin and
cortisol response after a citalopram infusion and presented
the highest platelet-rich plasma serotonin concentration. In
contrast, OCD patients with the same genotype (n = 6), all of
whom were non-responders, presented the lowest cortisol
responses and serotonin concentrations (not statistically
significant with regard to other subgroups except for the
Controls-CC genotype). The difference in magnitude is
surprising (prolactin response: CN-CC = 558.01¡80.12%;
NR-CC = 74.68¡49.13%; cortisol response: CN-CC = 317.48
¡206.23%; NR-CC = 20.53¡26.63%; p,0.001 after a Bon-
ferroni correction for both comparisons). Interestingly,
when we analyzed the frequency of the HTR1B CC homoz-
ygosity alone in the OCD group, there was an excess of this
genotype among the non-responders (p= 0.018; 6 of 32 NRs;
0 of 27 RPs; see Table 2). These data should be interpreted
cautiously because of the small subgroup size.
Nevertheless, we hypothesized what could account for
this genotype-group interaction and lead to a robust cortisol
response to citalopram in the CC-Control subgroup and
response in the CC-non responders subgroup. The 5-HT1Db
receptor is localized chiefly in the 5-HT terminals in which
its stimulation inhibits the release of 5-HT. Therefore, the
5-HT1Db receptor may be less active in the CC homozygous
members of the CN, allowing a more intense post-synaptic
serotonergic stimulation after citalopram infusion. The 5-
HT1Db receptor is also expressed, however, in the terminals
of nonserotonergic neurons, exerting heteroregulation of
neurotransmitter release and a postsynaptic receptor. The
latter occurs mainly in the basal ganglia. Chronic SRI
administration desensitizes the 5-HT1Db receptors (20).
This phenomenon, together with the desensitization of the
somatodendritic 5-HT1A receptor (21), leads to progressive
enhancement of 5-HT neurotransmission, correlating with a
therapeutic response (22). Therefore, in CC homozygous
patients, the observed blunted response could be related to
the chronic SRI exposure. We infer that a higher acute
serotonin response after SRI treatment could lead to more
intense adaptation after chronic SRI exposure and conse-
quently to a blunted cortisol response after a single dose of
citalopram. Accordingly, disrupted 5-HT1Db acute regula-
tion may cause other mechanisms to overcome an increased
serotonin transmission (e.g., post-synaptic receptor down-
regulation or decreased serotonin synthesis), which may
lead to an over-adaptation to chronic SRI exposure and
decreased SRI effectiveness. These hypotheses could be
evaluated in future studies.
As acknowledged, it may be premature to determine the
validity of the association of therapeutic response and
genetic polymorphisms because, as an alternative inter-
pretation, they may be in linkage disequilibrium with other
proximal polymorphisms that could affect the therapeutic
response.
Another limitation of this study was that the groups were
unmatched for ethnic origin. In populations of highly mixed
ethnicity, such as the Brazilian population, phenotyping
expressions of ethnicity, such as skin, hair and eye
pigmentation, is not viable (23,24). The sample size may
be the main methodological limitation of this study. Because
this was an exploratory study, we did not calculate the
sample power a priori and instead studied all of the
available subjects. It is worthwhile to note the unique
features of this sample. OCD patients were selected by their
long-term therapeutic responses; some of the resistant
patients have been in treatment for decades. Moreover, in
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this study, the evaluated groups were extreme. Non-
responders were unresponsive to at least three different
SRIs and remained symptomatic; responders met tight
remission criteria; and controls (healthy volunteers) who
neither mental health nor major medical problems. Many
putative patients and volunteers were excluded. These strict
criteria may have increased the study power but decreased
the external validity.
Because the data can be interpreted as false positive (at the
0.01 level of significance), further investigations using a larger
sample size are necessary to confirm our results. Prospective
studies with larger sample sizes and using selection criteria
according to the subjects’ genotype would be interesting. In
addition, the examined polymorphisms may be in linkage
disequilibrium with yet to be identified markers or genes that
contribute to OCD. Additionally, further research should be
performed to evaluate whether the endocrine response to
citalopram can be considered an endophenotype.
CONCLUSIONS
The conclusions of this study are as follows:
(1) The T allele of the 5-HTR2A T102C polymorphism was
more frequent among OCD patients.
(2) The CC genotype of the HTR2A C516T polymorphism
was more frequent among OCD patients who were
nonresponsive to several SRI trials than among the SRI-
responsive patients.
(3) The CC genotype of the HTR1B G681C polymorphism
was associated with higher cortisol and prolactin
responses to citalopram and a higher platelet-rich
plasma serotonin concentration among health volun-
teers. However, this pattern was not observed among
nonresponsive OCD patients with the same genotype
after chronic SRI treatment.
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